Posology : מינונים

4.2      Posology and method of administration
Patients should be made aware of the prophylactic nature of therapy with inhaled fluticasone propionate and that it should be taken regularly even when they are asymptomatic.

If patients find that relief with short-acting bronchodilator treatment becomes less effective or they need more inhalations than usual, medical attention must be sought.

Patients should be given an initial dose of nebulised fluticasone propionate which is appropriate for the severity of their disease. The dosage may be increased until control is achieved or reduced to the minimum effective dose according to the individual response.

Adults and adolescents over 16 years: 500-2000 micrograms twice daily.

Prescribers should be aware that fluticasone propionate is as effective as other inhaled steroids approximately at half the microgram daily dose. For example, a 100 mcg of fluticasone propionate is approximately equivalent to 200 mcg dose of beclometasone dipropionate (CFC containing) or budesonide.

Prescribers should be aware of the risks of systemic effects when using high doses of corticosteroids (see 4.4 special warnings and precautions for use and          4.8 undesirable effects).


The dose should be titrated down to the lowest dose at which effective control of asthma is maintained.

Children and adolescents from 4 to 16 years of age: 1000 mcg twice daily 
Special patient groups: There is no need to adjust the dose in elderly patients or those with hepatic or renal impairment.

Flixotide Nebules are for inhalation use only. They should be administered as an aerosol produced by a jet nebuliser, as directed by a physician. As drug delivery from nebulisers is variable, the manufacturer’s instructions for using the nebuliser must be followed.

Use of Flixotide Nebules with ultrasonic nebulisers is not generally recommended.

Flixotide Nebules should not be injected or administered orally.

It is advisable to administer Flixotide Nebules via a mouthpiece to avoid the possibility of atrophic changes to facial skin which may occur with prolonged use with a face-mask. When a face-mask is used, the exposed skin should be protected using a barrier cream, or the face should be thoroughly washed after treatment.